B. Riley analyst Anderson Schock initiated coverage of Anika Therapeutics (ANIK) with a Buy rating and $21 price target The company leverages its 30 years of hyaluronic acid production to develop and commercialize products in the osteoarthritis pain management and regenerative solutions spaces, the analyst tells investors in a research note. The firm says the osteoarthritis pain management business provides strong profitability and cash flow to fund the development of the company’s regenerative solutions portfolio. It expects Anika’s regenerative solutions product launches to be the main drivers of growth and margin expansion going forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK:
- Anika Therapeutics Announces COO Departure and Role Elimination
- Anika Therapeutics Faces Financial Strain Amid Geopolitical Tensions and Supply Chain Disruptions
- Anika Therapeutics’ Earnings Call: Growth Amid Challenges
- Anika Therapeutics price target lowered to $20 from $25 at Barrington
- Anika Therapeutics Reports Steady Growth and Strategic Focus